Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 766

TitleReference numberPublishedLast updated
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Voxelotor for treating haemolytic anaemia caused by sickle cell diseaseTA981
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Atogepant for preventing migraineTA973
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968

Results per page

  1. 10
  2. 25
  3. 50
  4. All